Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis

por Leonardi, C, Menter, A, Hamilton, T, Caro, I, Xing, B, Gottlieb, AB
Publicado 2008

Long‐term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE‐1)

por Papp, K., Menter, A., Leonardi, C., Soung, J., Weiss, S., Pillai, R., Jacobson, A.
Publicado 2020

Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis

por Tan, H, Gupta, P, Harness, J, Wolk, R, Chapel, S, Menter, A, Strober, B, Langley, RG, Krishnaswami, S, Papp, KA
Publicado 2013

Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)*

por Kimball, AB, Leonardi, C, Stahle, M, Gulliver, W, Chevrier, M, Fakharzadeh, S, Goyal, K, Calabro, S, Langholff, W, Menter, A
Publicado 2014

Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis o...

por Strober, B., Menter, A., Leonardi, C., Gordon, K., Lambert, J., Puig, L., Photowala, H., Longcore, M., Zhan, T., Foley, P.
Publicado 2020

Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

por Menter, A., Papp, K.A., Gooderham, M., Pariser, D.M., Augustin, M., Kerdel, F.A., Fakharzadeh, S., Goyal, K., Calabro, S., Langholff, W., Chavers, S., Naessens, D., Sermon, J., Krueger, G.G.
Publicado 2016